Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The fluoride controversy, where advocates and opponents argue in the media, is a distraction because the views of real and ...

The MG Windsor EV's ex-showroom price starts at Rs 9.99 lakh, excluding the battery cost. The car has received a price hike ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...

It's a new year, which means several new food items were deemed unsafe due to recalls by the U.S. Food and Drug Administration.

First details of the MG HS plug-in hybrid have been revealed. The Australian government’s Road Vehicle Regulator requires ...